TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER: PANITUMUMAB
The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most of the solid tumors. Panitumumab (Vectibix® Amgen) is a fully human monoclonal antibody that blocks the extracellular domain of the EGFR. This review summarizes on the pre- clinical and clinical development of panitumumab in col- orectal cancer. Panitumumab has been approved for col- orectal cancer because of their improvements in progres- sion-free survival and overall survival when associated with chemotherapy, as bevacizumab and cetuximab.
No comments » Add comment